A Review of Myeloablative vs Reduced Intensity/Non-Myeloablative Regimens in Allogeneic Hematopoietic Stem Cell Transplantations
- PMID: 28251017
- PMCID: PMC5322516
- DOI: 10.4274/balkanmedj.2017.0055
A Review of Myeloablative vs Reduced Intensity/Non-Myeloablative Regimens in Allogeneic Hematopoietic Stem Cell Transplantations
Abstract
Allogeneic hematopoietic stem cell transplantation (Allo-HSCT) is a curative treatment option for both malignant and some benign hematological diseases. During the last decade, many of the newer high-dose regimens in different intensity have been developed specifically for patients with hematologic malignancies and solid tumors. Today there are three main approaches used prior to allogeneic transplantation: Myeloablative (MA), Reduced Intensity Conditioning (RIC) and Non-MA (NMA) regimens. MA regimens cause irreversible cytopenia and there is a requirement for stem cell support. Patients who receive NMA regimen have minimal cytopenia and this type of regimen can be given without stem cell support. RIC regimens do not fit the criteria of MA and NMA: the cytopenia is reversible and the stem cell support is necessary. NMA/RIC for Allo-HSCT has opened a new era for treating elderly patients and those with comorbidities. The RIC conditioning was used for 40% of all Allo-HSCT and this trend continue to increase. In this paper, we will review these regimens in the setting of especially allogeneic HSCT and our aim is to describe the history, features and impact of these conditioning regimens on specific diseases.
Keywords: Conditioning regimens; myeloablative; non-myeloablative; reduced-intensity.
Conflict of interest statement
Conflict of Interest: No conflict of interest was declared by the authors.
Similar articles
-
The Incidence and Severity of Oral Mucositis among Allogeneic Hematopoietic Stem Cell Transplantation Patients: A Systematic Review.Biol Blood Marrow Transplant. 2016 Apr;22(4):605-616. doi: 10.1016/j.bbmt.2015.09.014. Epub 2015 Sep 26. Biol Blood Marrow Transplant. 2016. PMID: 26409924 Review.
-
Defining the intensity of conditioning regimens: working definitions.Biol Blood Marrow Transplant. 2009 Dec;15(12):1628-33. doi: 10.1016/j.bbmt.2009.07.004. Epub 2009 Sep 1. Biol Blood Marrow Transplant. 2009. PMID: 19896087 Free PMC article.
-
[Progress of research on allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning regimen for treatment of myelodysplastic syndrome - review].Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2008 Aug;16(4):969-74. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2008. PMID: 18718102 Review. Chinese.
-
Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.Dan Med Bull. 2007 May;54(2):112-39. Dan Med Bull. 2007. PMID: 17521527 Review.
-
Antithymocyte globulin in reduced-intensity conditioning regimen allows a high disease-free survival exempt of long-term chronic graft-versus-host disease.Biol Blood Marrow Transplant. 2014 Mar;20(3):370-4. doi: 10.1016/j.bbmt.2013.11.030. Epub 2013 Dec 4. Biol Blood Marrow Transplant. 2014. PMID: 24315846
Cited by
-
Advances in HIV Gene Therapy.Int J Mol Sci. 2024 Feb 28;25(5):2771. doi: 10.3390/ijms25052771. Int J Mol Sci. 2024. PMID: 38474018 Free PMC article. Review.
-
CD3-immunotoxin mediated depletion of T cells in lymphoid tissues of rhesus macaques.Heliyon. 2023 Aug 28;9(9):e19435. doi: 10.1016/j.heliyon.2023.e19435. eCollection 2023 Sep. Heliyon. 2023. PMID: 37810095 Free PMC article.
-
Influence of SPIO labelling on the function of BMSCs in chemokine receptors expression and chemotaxis.PeerJ. 2023 Jun 2;11:e15388. doi: 10.7717/peerj.15388. eCollection 2023. PeerJ. 2023. PMID: 37283891 Free PMC article.
-
Clinical Experience of Allogeneic Hematopoietic Stem Cell Transplantation in Elderly Patients Aged 60 Years and Older in South Korea.Yonsei Med J. 2023 Feb;64(2):123-132. doi: 10.3349/ymj.2022.0331. Yonsei Med J. 2023. PMID: 36719020 Free PMC article.
-
Allogeneic stem cell transplantation in the treatment of acute myeloid leukemia: An overview of obstacles and opportunities.World J Clin Cases. 2023 Jan 16;11(2):268-291. doi: 10.12998/wjcc.v11.i2.268. World J Clin Cases. 2023. PMID: 36686358 Free PMC article. Review.
References
-
- Passweg JR, Baldomero H, Gratwohl A, Bregni M, Cesaro S, Dreger P, et al. The EBMT activity survey:1990-2010. Bone Marrow Transplant. 2012;47:906–23. - PubMed
-
- Demirer T, Buckner CD, Appelbaum FR, Besinger WI, Sanders J, Lambert K, et al. Busulfan, cyclophosphamide and fractionated total body irradiation for autologous or syngeneic marrow transplantation for acute and chronic myelogenous leukemia: phase I dose escalation of busulfan based on targeted plasma levels. Bone Marrow Transplant. 1996;17:491–5. - PubMed
-
- Demirer T, Buckner CD, Appelbaum FR, Lambert K, Besinger WI, Clift R, et al. Busulfan, cyclophosphamide and fractionated total body irradiation for allogeneic marrow transplantation in advanced acute and chronic myelogenous leukemia: phase I dose escalation of busulfan based on targeted plasma levels. Bone Marrow Transplant. 1996;17:341–6. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources